{"id":"NCT02517905","sponsor":"Pacira Pharmaceuticals, Inc","briefTitle":"Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Local Administration of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2015-08-07","resultsPosted":"2020-12-10","lastUpdate":"2020-12-10"},"enrollment":166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dental Pain"],"interventions":[{"type":"DRUG","name":"Bupivacaine liposome","otherNames":["EXPAREL"]},{"type":"DRUG","name":"Placebo","otherNames":["Normal saline"]}],"arms":[{"label":"EXPAREL 133 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, double-blind, placebo-controlled study in subjects scheduled to undergo elective bilateral third molar extraction under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiographic evidence.","primaryOutcome":{"measure":"Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours","timeFrame":"0-48 hours","effectByArm":[{"arm":"EXPAREL 133 mg","deltaMin":178.9,"sd":10.3},{"arm":"Placebo","deltaMin":181.6,"sd":13.63}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8661"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Hypoesthesia oral","Dysgeusia","Nausea","Muscle contractions involuntary","Vomiting"]}}